{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:52:09Z","timestamp":1783947129335,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100018904","name":"Beijing\u2002Xisike\u2002Clinical\u2002Oncology\u2002Research\u2002Foundation","doi-asserted-by":"crossref","award":["No.\u2002Y-SY201901-0074"],"award-info":[{"award-number":["No.\u2002Y-SY201901-0074"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018904","name":"Beijing\u2002Xisike\u2002Clinical\u2002Oncology\u2002Research\u2002Foundation","doi-asserted-by":"crossref","award":["No.\u2002Y-SY201901-0074"],"award-info":[{"award-number":["No.\u2002Y-SY201901-0074"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018904","name":"Beijing\u2002Xisike\u2002Clinical\u2002Oncology\u2002Research\u2002Foundation","doi-asserted-by":"crossref","award":["No.\u2002Y-SY201901-0074"],"award-info":[{"award-number":["No.\u2002Y-SY201901-0074"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018904","name":"Beijing\u2002Xisike\u2002Clinical\u2002Oncology\u2002Research\u2002Foundation","doi-asserted-by":"crossref","award":["No.\u2002Y-SY201901-0074"],"award-info":[{"award-number":["No.\u2002Y-SY201901-0074"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018904","name":"Beijing\u2002Xisike\u2002Clinical\u2002Oncology\u2002Research\u2002Foundation","doi-asserted-by":"crossref","award":["No.\u2002Y-SY201901-0074"],"award-info":[{"award-number":["No.\u2002Y-SY201901-0074"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018904","name":"Beijing\u2002Xisike\u2002Clinical\u2002Oncology\u2002Research\u2002Foundation","doi-asserted-by":"crossref","award":["No.\u2002Y-SY201901-0074"],"award-info":[{"award-number":["No.\u2002Y-SY201901-0074"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018904","name":"Beijing\u2002Xisike\u2002Clinical\u2002Oncology\u2002Research\u2002Foundation","doi-asserted-by":"crossref","award":["No.\u2002Y-SY201901-0074"],"award-info":[{"award-number":["No.\u2002Y-SY201901-0074"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018904","name":"Beijing\u2002Xisike\u2002Clinical\u2002Oncology\u2002Research\u2002Foundation","doi-asserted-by":"crossref","award":["No.\u2002Y-SY201901-0074"],"award-info":[{"award-number":["No.\u2002Y-SY201901-0074"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018904","name":"Beijing\u2002Xisike\u2002Clinical\u2002Oncology\u2002Research\u2002Foundation","doi-asserted-by":"crossref","award":["No.\u2002Y-SY201901-0074"],"award-info":[{"award-number":["No.\u2002Y-SY201901-0074"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018904","name":"Beijing\u2002Xisike\u2002Clinical\u2002Oncology\u2002Research\u2002Foundation","doi-asserted-by":"crossref","award":["No.\u2002Y-SY201901-0074"],"award-info":[{"award-number":["No.\u2002Y-SY201901-0074"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018904","name":"Beijing\u2002Xisike\u2002Clinical\u2002Oncology\u2002Research\u2002Foundation","doi-asserted-by":"crossref","award":["No.\u2002Y-SY201901-0074"],"award-info":[{"award-number":["No.\u2002Y-SY201901-0074"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018904","name":"Beijing\u2002Xisike\u2002Clinical\u2002Oncology\u2002Research\u2002Foundation","doi-asserted-by":"crossref","award":["No.\u2002Y-SY201901-0074"],"award-info":[{"award-number":["No.\u2002Y-SY201901-0074"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Natural Science Foundation of Hubei Province","award":["2021CFB331"],"award-info":[{"award-number":["2021CFB331"]}]},{"name":"the Natural Science Foundation of Hubei Province","award":["2021CFB331"],"award-info":[{"award-number":["2021CFB331"]}]},{"name":"the Natural Science Foundation of Hubei Province","award":["2021CFB331"],"award-info":[{"award-number":["2021CFB331"]}]},{"name":"the Natural Science Foundation of Hubei Province","award":["2021CFB331"],"award-info":[{"award-number":["2021CFB331"]}]},{"name":"the Natural Science Foundation of Hubei Province","award":["2021CFB331"],"award-info":[{"award-number":["2021CFB331"]}]},{"name":"the Natural Science Foundation of Hubei Province","award":["2021CFB331"],"award-info":[{"award-number":["2021CFB331"]}]},{"name":"the Natural Science Foundation of Hubei Province","award":["2021CFB331"],"award-info":[{"award-number":["2021CFB331"]}]},{"name":"the Natural Science Foundation of Hubei Province","award":["2021CFB331"],"award-info":[{"award-number":["2021CFB331"]}]},{"name":"the Natural Science Foundation of Hubei Province","award":["2021CFB331"],"award-info":[{"award-number":["2021CFB331"]}]},{"name":"the Natural Science Foundation of Hubei Province","award":["2021CFB331"],"award-info":[{"award-number":["2021CFB331"]}]},{"name":"the Natural Science Foundation of Hubei Province","award":["2021CFB331"],"award-info":[{"award-number":["2021CFB331"]}]},{"name":"the Natural Science Foundation of Hubei Province","award":["2021CFB331"],"award-info":[{"award-number":["2021CFB331"]}]},{"name":"the Fund for Hepatobiliary and Pancreatic Malignant Tumours of the Hubei Chen Xiaoping Science and Technology Development Foundation","award":["CXPJJH12000001-2020344"],"award-info":[{"award-number":["CXPJJH12000001-2020344"]}]},{"name":"the Fund for Hepatobiliary and Pancreatic Malignant Tumours of the Hubei Chen Xiaoping Science and Technology Development Foundation","award":["CXPJJH12000001-2020344"],"award-info":[{"award-number":["CXPJJH12000001-2020344"]}]},{"name":"the Fund for Hepatobiliary and Pancreatic Malignant Tumours of the Hubei Chen Xiaoping Science and Technology Development Foundation","award":["CXPJJH12000001-2020344"],"award-info":[{"award-number":["CXPJJH12000001-2020344"]}]},{"name":"the Fund for Hepatobiliary and Pancreatic Malignant Tumours of the Hubei Chen Xiaoping Science and Technology Development Foundation","award":["CXPJJH12000001-2020344"],"award-info":[{"award-number":["CXPJJH12000001-2020344"]}]},{"name":"the Fund for Hepatobiliary and Pancreatic Malignant Tumours of the Hubei Chen Xiaoping Science and Technology Development Foundation","award":["CXPJJH12000001-2020344"],"award-info":[{"award-number":["CXPJJH12000001-2020344"]}]},{"name":"the Fund for Hepatobiliary and Pancreatic Malignant Tumours of the Hubei Chen Xiaoping Science and Technology Development Foundation","award":["CXPJJH12000001-2020344"],"award-info":[{"award-number":["CXPJJH12000001-2020344"]}]},{"name":"the Fund for Hepatobiliary and Pancreatic Malignant Tumours of the Hubei Chen Xiaoping Science and Technology Development Foundation","award":["CXPJJH12000001-2020344"],"award-info":[{"award-number":["CXPJJH12000001-2020344"]}]},{"name":"the Fund for Hepatobiliary and Pancreatic Malignant Tumours of the Hubei Chen Xiaoping Science and Technology Development Foundation","award":["CXPJJH12000001-2020344"],"award-info":[{"award-number":["CXPJJH12000001-2020344"]}]},{"name":"the Fund for Hepatobiliary and Pancreatic Malignant Tumours of the Hubei Chen Xiaoping Science and Technology Development Foundation","award":["CXPJJH12000001-2020344"],"award-info":[{"award-number":["CXPJJH12000001-2020344"]}]},{"name":"the Fund for Hepatobiliary and Pancreatic Malignant Tumours of the Hubei Chen Xiaoping Science and Technology Development Foundation","award":["CXPJJH12000001-2020344"],"award-info":[{"award-number":["CXPJJH12000001-2020344"]}]},{"name":"the Fund for Hepatobiliary and Pancreatic Malignant Tumours of the Hubei Chen Xiaoping Science and Technology Development Foundation","award":["CXPJJH12000001-2020344"],"award-info":[{"award-number":["CXPJJH12000001-2020344"]}]},{"name":"the Fund for Hepatobiliary and Pancreatic Malignant Tumours of the Hubei Chen Xiaoping Science and Technology Development Foundation","award":["CXPJJH12000001-2020344"],"award-info":[{"award-number":["CXPJJH12000001-2020344"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14581-3","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T07:39:28Z","timestamp":1755329968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment in advanced biliary tract cancer: results of a multicentre, randomised, phase II trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Xiao","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Sheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Mei","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Sheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng-hui","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"issue":"1","key":"14581_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","volume":"7","author":"PJ Brindley","year":"2021","unstructured":"Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, et al. Cholangiocarcinoma. Nat Rev Dis Primers. 2021;7(1):65.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"14581_CR2","doi-asserted-by":"publisher","first-page":"107327481772924","DOI":"10.1177\/1073274817729245","volume":"24","author":"NN Massarweh","year":"2017","unstructured":"Massarweh NN, El-Serag HB. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control. 2017;24(3):1073274817729245.","journal-title":"Cancer Control"},{"issue":"4","key":"14581_CR3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/sj.bjc.6605211","volume":"101","author":"JW Valle","year":"2009","unstructured":"Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - the UK ABC-01 study. Br J Cancer. 2009;101(4):621\u20137.","journal-title":"Br J Cancer"},{"issue":"1","key":"14581_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12885-019-5391-0","volume":"19","author":"PL Labib","year":"2019","unstructured":"Labib PL, Goodchild G, Pereira SP. Molecular pathogenesis of cholangiocarcinoma. BMC Cancer. 2019;19(1):185.","journal-title":"BMC Cancer"},{"issue":"2","key":"14581_CR5","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jhep.2019.10.009","volume":"72","author":"RK Kelley","year":"2020","unstructured":"Kelley RK, Bridgewater J, Gores GJ, Zhu AX. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72(2):353\u201363.","journal-title":"J Hepatol"},{"issue":"10","key":"14581_CR6","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1097\/TP.0000000000003114","volume":"104","author":"A Zaborowski","year":"2020","unstructured":"Zaborowski A, Heneghan HM, Fiore B, Stafford A, Gallagher T, Geoghegan J, et al. Neoadjuvant chemoradiotherapy and liver transplantation for unresectable hilar cholangiocarcinoma: the Irish experience of the Mayo protocol. Transplantation. 2020;104(10):2097\u2013104.","journal-title":"Transplantation"},{"issue":"6","key":"14581_CR7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jamasurg.2013.5137","volume":"149","author":"MN Mavros","year":"2014","unstructured":"Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg. 2014;149(6):565\u201374.","journal-title":"JAMA Surg"},{"issue":"Suppl 1","key":"14581_CR8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/liv.14086","volume":"39","author":"A Forner","year":"2019","unstructured":"Forner A, Vidili G, Rengo M, Bujanda L, Ponz-Sarvis\u00e9 M, Lamarca A. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):98\u2013107.","journal-title":"Liver Int"},{"issue":"6","key":"14581_CR9","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","volume":"7","author":"DY Oh","year":"2022","unstructured":"Oh DY, Lee KH, Lee DW, Yoon J, Kim TY, Bang JH, et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol Hepatol. 2022;7(6):522\u201332.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"14581_CR10","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","volume":"15","author":"D Malka","year":"2014","unstructured":"Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardiere C, Boucher E, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014;15(8):819\u201328.","journal-title":"Lancet Oncol"},{"issue":"3","key":"14581_CR11","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1158\/2159-8290.CD-11-0242","volume":"2","author":"KK Frese","year":"2012","unstructured":"Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, et al. Nab-paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2012;2(3):260\u20139.","journal-title":"Cancer Discov"},{"issue":"1","key":"14581_CR12","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1038\/s41467-022-31704-7","volume":"13","author":"B Wang","year":"2022","unstructured":"Wang B, Sun T, Zhao Y, Wang S, Zhang J, Wang Z, et al. A randomized phase 3 trial of gemcitabine or nab-paclitaxel combined with cisplatin as first-line treatment in patients with metastatic triple-negative breast cancer. Nat Commun. 2022;13(1):4025.","journal-title":"Nat Commun"},{"issue":"31","key":"14581_CR13","doi-asserted-by":"publisher","first-page":"50624","DOI":"10.18632\/oncotarget.9562","volume":"7","author":"Y Fan","year":"2016","unstructured":"Fan Y, Jiang Y, Zhou X, Chen Q, Huang Z, Xu Y, et al. Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma. Oncotarget. 2016;7(31):50624\u201334.","journal-title":"Oncotarget"},{"issue":"17","key":"14581_CR14","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21(17):3194\u2013200.","journal-title":"J Clin Oncol"},{"issue":"3","key":"14581_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00280-023-04512-z","volume":"91","author":"LAW de Jong","year":"2023","unstructured":"de Jong LAW, Lambert M, van Erp NP, de Vries L, Chatelut E, Ottevanger PB. Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer. Cancer Chemother Pharmacol. 2023;91(3):247\u201356.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"14581_CR16","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.surg.2022.09.028","volume":"173","author":"SH Choi","year":"2023","unstructured":"Choi SH, Kang I, Lee SH, Kang B, Cheon J, Kim DJ, et al. Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma. Surgery. 2023;173(2):280\u20138.","journal-title":"Surgery"},{"issue":"6","key":"14581_CR17","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","volume":"5","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, et al. Gemcitabine, cisplatin, and nab-Paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 2019;5(6):824\u201330.","journal-title":"JAMA Oncol"},{"issue":"17","key":"14581_CR18","doi-asserted-by":"publisher","first-page":"5164","DOI":"10.7150\/jca.59794","volume":"12","author":"BX Li","year":"2021","unstructured":"Li BX, Chen XJ, Ding TJ, Liu YH, Ma TT, Zhang GL, et al. Potentially overestimated efficacy of nanoparticle albumin-bound paclitaxel compared with solvent-based paclitaxel in breast cancer: a systemic review and meta-analysis. J Cancer. 2021;12(17):5164\u201372.","journal-title":"J Cancer"},{"issue":"18","key":"14581_CR19","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703.","journal-title":"N Engl J Med"},{"key":"14581_CR20","doi-asserted-by":"publisher","unstructured":"Peng L, Bu Z, Ye X, Zhou Y, Zhao Q. Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis. Eur J Cancer Care. 2017;26(5).\u00a0https:\/\/doi.org\/10.1111\/ecc.12407.","DOI":"10.1111\/ecc.12407"},{"issue":"4","key":"14581_CR21","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3892\/mco.2017.1373","volume":"7","author":"Y Yasuda","year":"2017","unstructured":"Yasuda Y, Nomizo T, Ozasa H, Funazo T, Tsuji T, Yoshida H, et al. Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease. Mol Clin Oncol. 2017;7(4):677\u201380.","journal-title":"Mol Clin Oncol"},{"issue":"12","key":"14581_CR22","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1001\/jamaoncol.2018.3277","volume":"4","author":"V Sahai","year":"2018","unstructured":"Sahai V, Catalano PJ, Zalupski MM, Lubner SJ, Menge MR, Nimeiri HS, et al. Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4(12):1707\u201312.","journal-title":"JAMA Oncol"},{"issue":"1","key":"14581_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.21037\/hbsn-21-172","volume":"12","author":"W Zhang","year":"2023","unstructured":"Zhang W, Sun Y, Jiang Z, Qu W, Gong C, Zhou A. Nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule (S-1) as first-line treatment for advanced biliary tract adenocarcinoma: a phase 2 clinical trial. Hepatobiliary Surg Nutr. 2023;12(1):37\u201344.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"5","key":"14581_CR24","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.1111\/ajco.13599","volume":"18","author":"R Woodford","year":"2022","unstructured":"Woodford R, Brungs D, Leighton C, Grimison P, Sjoquist KM, Becker T, et al. Combination chemotherapy with NAB(\u00ae) -paclitaxel and capecitabine for patients with advanced biliary tract cancer (NAP-CAPABIL Pilot Study). Asia Pac J Clin Oncol. 2022;18(5):e220\u20136.","journal-title":"Asia Pac J Clin Oncol"},{"key":"14581_CR25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jconrel.2014.03.016","volume":"182","author":"J Zhang","year":"2014","unstructured":"Zhang J, Miao L, Guo S, Zhang Y, Zhang L, Satterlee A, et al. Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model. J control Release. 2014;182:90\u20136.","journal-title":"J control Release"},{"issue":"16","key":"14581_CR26","doi-asserted-by":"publisher","first-page":"4775","DOI":"10.1158\/0008-5472.CAN-16-0188","volume":"76","author":"M Cadamuro","year":"2016","unstructured":"Cadamuro M, Spagnuolo G, Sambado L, Indraccolo S, Nardo G, Rosato A, et al. Low-dose paclitaxel reduces S100A4 nuclear import to inhibit invasion and hematogenous metastasis of cholangiocarcinoma. Cancer Res. 2016;76(16):4775\u201384.","journal-title":"Cancer Res"},{"issue":"6","key":"14581_CR27","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3324\/haematol.2021.279512","volume":"107","author":"DJ Kuter","year":"2022","unstructured":"Kuter DJ. Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies. Haematologica. 2022;107(6):1243\u201363.","journal-title":"Haematologica"},{"issue":"7","key":"14581_CR28","first-page":"3445","volume":"11","author":"Y Chen","year":"2021","unstructured":"Chen Y, Liu R, Li C, Song Y, Liu G, Huang Q, et al. Nab-paclitaxel promotes the cancer-immunity cycle as a potential immunomodulator. Am J Cancer Res. 2021;11(7):3445\u201360.","journal-title":"Am J Cancer Res"},{"issue":"3","key":"14581_CR29","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/01635581.2022.2156552","volume":"75","author":"J Guo","year":"2023","unstructured":"Guo J, Zhao J, Gu M, Hou J, Xu T, Jiang Y, et al. Association between body composition and peripheral neurotoxicity in cancer patients from North China taking Nab-paclitaxel. Nutr Cancer. 2023;75(3):805\u201314.","journal-title":"Nutr Cancer"},{"issue":"11","key":"14581_CR30","doi-asserted-by":"publisher","first-page":"e1024","DOI":"10.1634\/theoncologist.2017-0664","volume":"24","author":"E Ciruelos","year":"2019","unstructured":"Ciruelos E, Apell\u00e1niz-Ruiz M, Cantos B, Martinez-J\u00e1\u00f1ez N, Bueno-Mui\u00f1o C, Echarri MJ, et al. A pilot, phase II, randomized, open-label clinical trial comparing the neurotoxicity of three dose regimens of nab-paclitaxel to that of solvent-based paclitaxel as the first-line treatment for patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer. Oncologist. 2019;24(11):e1024\u201333.","journal-title":"Oncologist"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14581-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14581-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14581-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T14:53:18Z","timestamp":1757429598000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14581-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14581"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14581-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5762910\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,16]]},"assertion":[{"value":"4 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has obtained informed consent from participants. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. This study was registered with the Ethics Committee of Registered Clinical Trials in China and has undergone ethical review under the ethical review symbol: ChiECRCT-20180167.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have intellectually contributed to this manuscript and provided consent for submission and publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1321"}}